Privately-held US biotech firm Mersana Therapeutics and Japan’s Takeda Pharmaceutical (TYO: 4502) have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the USA and Canada.
The deal also expands an existing collaboration between the companies to provide Takeda with additional access to Mersana’s Fleximer antibody-drug conjugate (ADC) platform (The Pharma Letter January 13) and grants Mersana an option at the end of Phase I to co-develop and co-commercialize one of these programs in the USA. In addition, the companies will co-develop new payloads for use with ADCs.
Financial terms
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze